Medcura key facts
as of Oct 2026- Developer of biopolymer-based hemostatic device designed to manage surgical bleeding in clinical, military, and consumer environments.
- Medcura is valued at approximately $112.0M as of Oct 2026, set at its later-stage round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $55.9M across 4 recorded rounds; the latest was Early Stage VC ($28.5M) in Apr 2025.
- Notable investors include US National Science Foundation, United States Department of War, TEDCO, New York Angels, Robin Hood Ventures — 18 tracked in total.
- Medcura has filed 5 Form Ds with the SEC since 2020, most recently Jul 2025 ($28.5M sold to 174 investors).
- Status: Privately Held (backing).
Valued at $112.0M at its later-stage round, Jul 2025. Nothing has traded since.
- ·The complete investor list: 18 names
- ·Watch Medcura: the Monday email on marks, rounds and moves
Medcura funding rounds
4 roundsWho backs Medcura
18+Medcura valuation
Medcura was valued at $112 million at its later-stage round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Medcura raised?
Medcura has raised $55.9 million across 4 recorded rounds since 2020. The largest was a $3.5 million seed round in Oct 2021; the most recent was a $28.5 million early-stage round in Apr 2025.
Medcura has filed 5 Form Ds with the SEC since 2020, most recently in Jul 2025 ($28.5 million sold to 174 investors).
Medcura investors
18 investors are on record for Medcura, including US National Science Foundation, United States Department of War, TEDCO and New York Angels. By type, the record holds 2 family offices, 2 angel investors and 1 venture capital firm. The early-stage round in Apr 2025 drew 174 investors.
About Medcura
Developer of biopolymer-based hemostatic device designed to manage surgical bleeding in clinical, military, and consumer environments. The company's device utilizes hydrophobically modified natural biomaterials that mechanically adhere to bleeding sites without swelling, reduce risk in confined anatomical spaces, maintain structural integrity during application, and offer cost-effective bleeding control, enabling surgeons and healthcare providers to improve safety, reduce complications, and optimize procedural efficiency.
- Sector
- Healthcare
- HQ
- Riverdale, MD, United States
- Founded
- 2007
- Employees
- 35
- Website
- medcurainc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.